Preoperative radiosurgery for brain metastases (PREOP-1): A feasibility trial

S Rogers; L Schwyzer; N Lomax; S Alonso; T Lazeroms; S Gomez; K Diahovets; I Fischer; S Schwenne; A Ademaj; S Berkmann; A Tortora; S Marbacher; L Remonda; G A Schubert; O Riesterer

doi:10.1016/j.ctro.2024.100798

Preoperative radiosurgery for brain metastases (PREOP-1): A feasibility trial

Clin Transl Radiat Oncol. 2024 Jun 1:47:100798. doi: 10.1016/j.ctro.2024.100798. eCollection 2024 Jul.

Authors

S Rogers¹, L Schwyzer², N Lomax¹, S Alonso¹, T Lazeroms¹, S Gomez¹, K Diahovets³, I Fischer³, S Schwenne¹, A Ademaj^{1

4}, S Berkmann⁵, A Tortora⁶, S Marbacher², L Remonda⁷, G A Schubert^{2

8}, O Riesterer¹

Affiliations

¹ Radiation Oncology Centre KSA-KSB, Kantonsspital Aarau, Tellstrasse, 5001 Aarau, Switzerland.
² Dept. of Neurosurgery, Kantonsspital Aarau, Tellstrasse, 5001 Aarau, Switzerland.
³ Dept. of Neuropathology, Kantonsspital Aarau, Tellstrasse, 5001 Aarau, Switzerland.
⁴ Doctoral Clinical Science Program, Medical Faculty, University of Zürich, 8032 Zürich, Switzerland.
⁵ Neurochirurgie Baden, Husmatt 1, 5405 Baden, Switzerland.
⁶ Dept. of Neurosurgery, Presidio Ospedaliero Universitario Santa Maria Della Misericordia Udine, Italy.
⁷ Dept. of Neuroradiology, Kantonsspital Aarau, Tellstrasse, 5001 Aarau, Switzerland.
⁸ Dept. of Neurosurgery, RWTH Aachen University, Aachen, Germany.

Abstract

Purpose: Preoperative radiosurgery (SRS) of brain metastases (BM) aims to achieve cavity local control with a reduction in leptomeningeal relapse (LMD) and without additional radionecrosis compared to postoperative SRS. We present the final results of a prospective feasibility trial of linac-based stereotactic radiosurgery (SRS) prior to neurosurgical resection of a brain metastasis (PREOP-1).

Methods: Eligibility criteria included a BM up to 4 cm in diameter for elective resection. The primary endpoint was the feasibility of delivering linac-based preoperative SRS in all patients prior to anticipated gross tumour resection. Secondary endpoints included rates of LMD, local control and overall survival. Exploratory endpoints were the level of expression of immunological and proliferative markers.

Results: Thirteen patients of median age 65 years (range 41-77) were recruited. Twelve patients (92 %) received preoperative radiosurgery and metastasectomy and one patient went directly to surgery and received postoperative SRS, thus the primary endpoint was not met. The median time between referral and preoperative SRS was 6.5 working days (1-10) and from SRS to neurosurgery was 1 day (0-5). The median prescribed dose was 16 Gy (14-19) to a median planning target volume of 12.7 cm³ (5.9-26.1). Five patients completed 12-month follow-up after preoperative SRS without local recurrence or leptomeningeal disease. The patient who received postoperative FSRT developed LMD after six months. There was one transient toxicity (grade 2 alopecia) and nine patients have died from extracranial causes. Patients reported significant improvement in motor weakness at 6 months (P = 0.04). No pattern in changes of marker expression was observed.

Conclusion: In patients with large brain metastasis without raised intracranial pressure, linac-based preoperative SRS was feasible in 12/13 patients and safe in 12/12 patients without any surgical delay or intracranial complications.

Keywords: Brain; Feasibility; Metastases; Preoperative; Radiosurgery; Trial.